Humira® 40mg Syringe 0.8mL Subcutaneous Injection Special Investigation in Patients With Intestinal Behcet's Disease
Phase of Trial: Phase IV
Latest Information Update: 27 Mar 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Behcet's syndrome
- Focus Adverse reactions
- Sponsors AbbVie
- 31 Aug 2018 Biomarkers information updated
- 30 May 2017 Status changed from active, no longer recruiting to completed.
- 03 Aug 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2017.